104860-32-4

Basic information

• Product Name: 1-Piperidinecarboxylicacid,4-amino-3-methoxy-,ethylester,trans-(9CI)
• Synonyms: 1-Piperidinecarboxylicacid,4-amino-3-methoxy-,ethylester,trans-(9CI)
• CAS NO: 104860-32-4
• Molecular Formula: C9H18N2O3
• Molecular Weight: 0
• Product Categories: AMINOACID
• Mol File: 104860-32-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Piperidinecarboxylicacid,4-amino-3-methoxy-,ethylester,trans-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylicacid,4-amino-3-methoxy-,ethylester,trans-(9CI)(104860-32-4)
• EPA Substance Registry System: 1-Piperidinecarboxylicacid,4-amino-3-methoxy-,ethylester,trans-(9CI)(104860-32-4)

Safety Data

• Hazardous Substances Data: 104860-32-4(Hazardous Substances Data)

Upstream product

• 100-46-9 benzylamine 
• 83863-72-3 (-)-ethyl 3-methoxy-4-oxo-1-piperidine-carboxylate 
• 83898-43-5 ethyl 3-hydroxy-4,4-dimethoxy-1-piperidinecarboxylate 
• 83863-71-2 ethyl (3RS,4SR)-4-amino-3-methoxypiperidine-1-carboxylic acid hydrochloride Salt 
• 83863-73-4 (-)-ethyl 3,4,4-trimethoxy-1-piperidinecarboxylate 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 
• 907543-85-5 ethyl (3R,4S)-4-(benzylamino)-3-methoxypiperidine-1-carboxylate 
• 907543-86-6 ethyl (3S,4R)-4-(benzylamino)-3-methoxypiperidine-1-carboxylate 

Relevant articles and documents

Discovery and SAR of N-(1-((substituted piperidin-4-yl)methyl)-3-methoxypiperidin-4-yl)-2-methoxybenzamide derivatives: 5-Hydroxytryptamine receptor 4 agonist as a potent prokinetic agent

A series of novel benzamide derivatives, altering the 4-fluorophenylalkyl moiety in cisapride, were synthesized as 5-HT4 receptor agonists, and SAR of these analogs was examined on in vitro and in vivo prokinetic activities. These compounds were synthesized for high 5-HT4 receptor binding affinities and low hERG affinities. Several types of analogs were obtained and screened for 5-HT4 binding, hERG blocking, agonism, and gastric emptying assessment. Among the analogues, compound 23g showed promising results compared with the other analogs with respect to gastric emptying rates in rats. Therefore, we suggest that it may be a clinical candidate for the development of a potent prokinetic agent to treat GI disorders.

CONDENSED PYRIDINE COMPOUND

The present invention provides a compound having excellent JAK3 inhibitory activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases. As a result of investigations with respect to novel condensed heterocyclic derivatives, the inventors have verified that a condensed pyridine compound has excellent JAK3 inhibitory activity, thereby completing the present invention. More specifically, it has been verified that since the compound according to the present invention has inhibitory activity against JAK3, the compound is useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transduction (e.g., rejection during live organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, rheumatism, psoriasis and atherosclerotic disease), or diseases caused by abnormal cytokine signal transduction (e.g., cancer and leukemia).

DIMETHYLBENZOFURAN AND DIMETHYLBENZOPYRAN DERIVATIVES AND THEIR USE AS 5-HT3 ANTAGONISTS

Method of treating 5-HT 3-mediated disorders, which comprises systemic administration of an effective amount of a compound of formula (I) STR1 the pharmaceutically acceptable acid addition salt forms and the stereochemically isomeric forms thereof, wherein R 1 and R 2 represent hydrogen, or R 1 and R 2 taken together form a bivalent radical of formula--CH=CH--CH=CH--(a),--CH=C(Cl)--CH= CH--(b) or--CH=CH--C(Cl)=CH--(c); n represents 2, 3 or 4; R. sup.3 represents hydrogen or methoxy; m represents 1 or 2; R 4 represents hydrogen, amino or C 1-3-alkylcarbonylamino; and R 5 represents hydrogen or halo; novel compounds; compositions; processes for preparing novel compounds and intermediates.